As of May 25
| +0.0039 / +0.79%|
The 3 analysts offering 12-month price forecasts for Aviragen Therapeutics Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 2.50. The median estimate represents a +902.20% increase from the last price of 0.50.
The current consensus among 3 polled investment analysts is to Hold stock in Aviragen Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.